Filing Flows › ResMed (RMD) › Recalls, complaints & regulation
ResMed (RMD): recalls and clinical trials
ResMed (RMD) beyond its filings: 1 recall in the last 12 months (9 in five years, 9 Class I); 13 active clinical trials.
Latest recalls
- 2026-08-05 · FDA device · Resmed Astral 100/150 Resmed Astral 100/50 is a ventilator system that provides continuous or intermittent ventilatory support for patients weighing more tha
- 2023-12-27 · FDA device · AirTouch F20 Full Face Mask and User Guide
- 2023-12-27 · FDA device · AirTouch N20 Nasal Mask and User Guide
- 2023-12-27 · FDA device · AirFit F30 Full Face Mask and User Guide
- 2023-12-27 · FDA device · AirFit N10 Nasal Masks and User Guide
- 2023-12-27 · FDA device · AirFit F20 Full Face Mask and User Guide
- 2023-12-27 · FDA device · AirFit F30i Full Face Mask and User Guide
- 2023-12-27 · FDA device · AirFit N20 Nasal Mask and User Guide
ResMed's latest quarter
ResMed, Q1 FY27: revenue $1.4B (+6% year over year), operating margin 32.0%, net earnings $418M, operating cash flow $422M. The chart follows the revenue to costs, profit and cash.
Questions
Has ResMed had any recalls?
9 recalls on file over five years from the FDA, CPSC and NHTSA; 1 in the last 12 months.
How many clinical trials does ResMed have?
13 active studies on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.